T he Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program (NCEP) issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, five major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. An NCEP working group reviewed the results of these recent trials and assessed their implications for cholesterol management. These clinical trials strongly support the ATP III recommendation that LDL-cholesterol (LDL-C) should be the primary target of lipid-lowering therapy. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of LDL-C Ͻ100 mg/dL. In fact, they add to the growing evidence supporting the concept that, for LDL-C in high-risk patients, "the lower, the better" for reducing risk for major cardiovascular events ( Figure) . Although recent clinical trials focused on drug therapies for LDL lowering, the NCEP update affirms that therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. TLC has the potential to reduce cardiovascular risk through several mechanisms beyond LDL lowering. Recent clinical trials support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm for LDL lowering are presented in the Table 1 and are summarized in Table 2 . In high-risk persons, ATP III established that the recommended LDL-C goal is Ͻ100 mg/dL; when triglycerides are high (Ն200 mg/dL), a secondary goal is a non-HDL-C Ͻ130 mg/dL. According to the update, when risk is very high, an LDL-C goal of Ͻ70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, based on available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C Ͻ100 mg/dL. For those very high risk patients who have a high triglyceride, a level of non-HDL-C of Ͻ100 mg/dL corresponds to an LDL-C level of Ͻ70 mg/dL. Identifying a very high risk patient depends on clinical judgment. Examples of such patients include those with established cardiovascular disease plus (1) multiple major risk factors (especially diabetes), (2) severe and poorly controlled risk factors (especially continued cigarette smoking), (3) multiple risk factors of the metabolic syndrome (especially high triglyceride Ն200 mg/dL plus non-HDL-C Ն130 mg/dL with low HDL-C [Ͻ40 mg/dL]) and (4) those with acute coronary syndromes. Moreover, when any high-risk patient has high triglyceride or low HDL-C, consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug.
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For moderately high-risk persons (2ϩ risk factors and 10year risk 10% to 20%), the recommended LDL-C goal is Ͻ130 mg/dL; but an LDL-C goal Ͻ100 mg/dL is a therapeutic option based on recent trial evidence. The latter option extends also to moderately high risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug Log-linear relationship between LDL-cholesterol levels and relative risk for coronary heart disease (CHD). This relationship is consistent with a large body of epidemiological data and with data available from clinical trials of LDL-lowering therapy. These data suggest that for every 30 mg/dL change in LDL-C, the relative risk for CHD is changed in proportion by Ϸ30%. The relative risk is set at 1.0 for LDL-Cϭ40 mg/dL therapy is used in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglyceride, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cut points of therapy. § Almost all people with 0 -1 risk factor have a 10-year risk Ͻ10%, and 10-year risk assessment in people with 0 -1 risk factor is thus not necessary. ¶ Very high risk favors the optional LDL-C goal of Ͻ70 mg/dL ʈ Optional LDL-C goal Ͻ100 mg/dL. **Any person at high-risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglyceride, low HDL-C, or metabolic syndrome) is a candidate for therapeutic lifestyle changes to modify these risk factors regardless of LDL-C level.
† † When LDL-lowering drug therapy is used, it is advised that intensity of therapy be sufficient to achieve at least a 30%-40% reduction in LDL-C levels. ‡ ‡ If baseline LDL-C is Ͻ100 mg/dL, institution of an LDL-lowering drug is a therapeutic option based on available clinical trial results. If a high-risk person has high triglycerides or low HDL-C, combining a fibrate or nicotinic acid with an LDL-lowering drug can be considered. § § For moderately high-risk persons, when LDL-C level is 100 -129 mg/dL, at baseline or on lifestyle therapy, initiation of an LDL-lowering drug to achieve an LDL-C level Ͻ100 mg/dL is a therapeutic option based on available clinical trial results.
TABLE 2. Recommendations for Modifications to Footnote the ATP III Treatment Algorithm for LDL-Cholesterol (LDL-C)
Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. TLC has the potential to reduce cardiovascular risk through several mechanisms beyond LDL lowering.
In high-risk persons, the recommended LDL-C goal is Ͻ100 mg/dL.
An LDL-C goal of Ͻ70 mg/dL is a therapeutic option based on available clinical trial evidence, especially for patients at very high risk.
If LDL-C is Ն100 mg/dL, an LDL-lowering drug is indicated simultaneously with lifestyle changes.
If baseline LDL-C is Ͻ100 mg/dL, institution of an LDL-lowering drug to achieve an LDL-C level Ͻ70 mg/dL is a therapeutic option based on available clinical trial evidence.
If a high-risk person has high triglycerides or low HDL-C, consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. When triglycerides are Ն200 mg/dL, non-HDL-C is a secondary target of therapy, with a goal 30 mg/dL higher than the identified LDL-C goal For moderately high-risk persons (2ϩ risk factors and 10-year risk 10%-20%), the recommended LDL-C goal is Ͻ130 mg/dL; an LDL-C goal Ͻ100 mg/dL is a therapeutic option based on available clinical trial evidence. When LDL-C level is 100 -129 mg/dL, at baseline or on lifestyle therapy, initiation of an LDL-lowering drug to achieve an LDL-C level Ͻ100 mg/dL is a therapeutic option based on available clinical trial evidence.
Any person at high-risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglyceride, low HDL-C, or metabolic syndrome) is a candidate for therapeutic lifestyle changes to modify these risk factors regardless of LDL-C level.
When LDL-lowering drug therapy is used in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30%-40% reduction in LDL-C levels.
For people in lower-risk categories, recent clinical trials do not modify the goals and cut points of therapy.
